|Bid||2.5100 x 900|
|Ask||3.1900 x 1100|
|Day's Range||2.9700 - 3.2900|
|52 Week Range||2.9000 - 22.0800|
|Beta (5Y Monthly)||5.82|
|PE Ratio (TTM)||2.60|
|Earnings Date||May 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
Subscribe to Yahoo Finance Plus to view Fair Value for APVO
Alligator Bioscience AB("Alligator") and Aptevo Therapeutics ("Aptevo") today announced that the US Food and Drug Administration (FDA) has issued a "may proceed" notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.
/ Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results and business highlights for the quarter ended June 30, 2022.
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to DateCohort 3 Monotherapy Patient Achieved Bone Marrow Complete RemissionCompany Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable and on APVO436 After 18 Months of TreatmentSEATTLE, WA / ACCESSWIRE / June 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel im